

PREPRINT

## Continuing COVID-19 Vaccination of Front-Line Workers in BC with the AstraZeneca Vaccine: Benefits in the Face of Increased Risk for Prothrombotic Thrombocytopenia

Amin Adibi<sup>a</sup>

<sup>a</sup>Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

### ARTICLE HISTORY

Compiled April 6, 2021

### ABSTRACT

Recently, the National Advisory Committee on Immunization (NACI) recommended against using the AstraZeneca COVID-19 vaccine pending further review of the risk for Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT). Using straightforward calculations and based on current evidence, we propose that even if the risk is found to be causally related to the AstraZeneca vaccine, the benefits of continuing immunization of essential workers with AstraZeneca by far outweigh the risk. We consider the case of British Columbia as an example. The province is expected to receive an additional 246700 doses of AstraZeneca vaccine through US and COVAX until April 11th, enough to provide the first dose of vaccine to all unvaccinated front-line workers. We estimate that if British Columbia continues the front-line worker vaccination program as many as 600 lives could be saved for an expected mortality of only 1 person, even if all essential workers were under 55 and assuming the highest estimated rate of 1 in 100,000 currently reported for VIPIT.

### KEYWORDS

COVID19; astrazeneca; vaccination; essentialworkers; clots; thrombocytopenia; harm-benefit; BC

## 1. Background

Recently, NACI recommended against using AstraZeneca COVID-19 Vaccine for Canadians under the age of 55, due to concerns about the incidence of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) based on European reports (NACI 2021). On March 18, 2021, the European Medicines Agency estimated the incidence of VIPIT at approximately 1 per 1,000,000 people vaccinated with the AstraZeneca vaccine (EMA 2021). A higher estimated rate of 1 per 100,000 by the Paul-Ehrlich Institut in Germany was published on March 19th (PEI 2021). It was this higher rate reported by the Paul-Ehrlich Institut that led NACI to recommend against using this vaccine in adults under 55 years old (NACI 2021). BC had initially slated the AstraZeneca vaccine for outbreak control and front-line workers vaccination program. on March 29th and following NACI's recommendation, BC paused using the AstraZeneca vaccine for those under 60 and put the front-line workers vaccination program on hold.

On April 1st, the UK Medicines & Healthcare Products Regulatory Agency updated its own previously reported data to report a total of 22 cerebral venous sinus thrombosis (CVST) and 8 other clot-related events from 18.1 million doses of the AstraZeneca vaccine (total incidence rate 1 in 600,000) (MHRA 2021).

Canadian provinces are expected to receive 1.5 million doses of the AstraZeneca vaccine from the US and another 316,800 doses from the COVAX program between now and April 11th (Government of Canada 2021). British Columbia expects to receive 246,700 doses from these two AstraZeneca deliveries, enough to finish providing the first dose to all remaining front-line workers.

The 300,690 doses of Pfizer-BioNTech and 105,900 doses of Moderna vaccines expected within the same time frame are currently allocated for the priority groups, indigenous population, and age-based vaccination campaign currently vaccinating those in their 70s. The AstraZeneca vaccine was initially slated for essential workers due to its easier handling and storage requirements. If it is logistically possible to switch the vaccine allocation for above 55 years old age groups to the AstraZeneca vaccine and use either Pfizer-BioNTech or Moderna vaccines for younger front-line workers without delay, that might be the preferred approach. However, if that is not logistically feasible, one might ask whether the benefits of deploying the AstraZeneca vaccine for front-line workers outweigh the rate but serious risk for VIPIT.

Harm-benefit of the administering the AZ doses to younger front-line workers can be analyzed from either a societal or a personal perspective. From a societal perspective and assuming a utilitarian framework, we can estimate compare outcomes such as deaths, life years lost, or Quality-Adjusted Life Years (QALYs) under different scenarios. However, a net-beneficial intervention at the societal level does not necessarily translate to a net-benefit at the personal level, as the those who carry the burden of risk may be different from those who are likely to benefit from the intervention.

Whether explicitly stated or not, the choice of the outcome is affected by value judgments as well. Choosing life-years lost as an outcome, for instance, favours younger people. To make things more complex, roll-out decisions can get tangled in all sorts of societal issues, including public trust in not only COVID-19 vaccines but vaccine hesitancy in general. Ultimately, in dynamic situations like this where the evidence is uncertain and evolving, vaccine roll-out decision are judgment calls that need to take a complex network of medical, epidemiological, ethical, logistics, and societal considerations into account.

Here, we provide a preliminary harm-benefit analysis of immediate vaccination of all front-line workers with the AstraZeneca COVID-19 vaccine. We based our analysis on mortality alone, and explore the risk both from a societal and personal perspective, and touch on some important ethical and practical considerations.

## 2. Methods

### 2.1. *COVID-19 Transmission Model*

We estimated benefits of the AstraZeneca COVID-19 matrix using a BC-specific COVID-19 compartmental model by Mulberry and colleagues that takes into account transmission, age-based contact structure, front-line worker status, and rising  $R_0$  due to variants of concern (Mulberry et al. 2021). The Mulberry model itself was based on the transmission model by Bubar et al (Bubar et al. 2021).

We ran the model from January 2021 to September 2021, when we expect the

vaccination campaign to conclude.

### 3. Results

#### 3.1. Harm-Benefit From A Societal Perspective

Assuming that BC allocates all 246,700 doses to front-line workers, we can estimate the expected number of deaths due to VIPIT,  $E(\text{death})_{VIPIT}$ , as shown below. To err on the side of caution, we assume that each dose of the vaccine is independently associated with the risk for VIPIT and that all recipients are under 55 and as such at higher risk for VIPIT. We also assume that there is enough uptake that BC is able to administer all these doses.

$$E(\text{death})_{VIPIT} = d \times P(VIPIT|AZ) \times P(\text{death}|VIPIT, AZ)$$

where  $d$  is the number of doses administered,  $P(VIPIT|AZ)$  is the risk of VIPIT after receiving each dose, and  $P(\text{death}|VIPIT, AZ)$  is the case fatality for VIPIT.

To err on the side of caution, we will follow NACI's lead and assume the highest reported rate of VIPIT, which is 1 in 100,000 recipients, so  $P(VIPIT|AZ) = \frac{1}{100,000}$ . On the other hand, as reported by NACI, case fatality due to VIPIT is currently estimated at 40% but is likely to decrease as there will be more awareness and better early treatment. Again to err on the side of caution, we'll keep the estimate at 40%:  $P(\text{death}|VIPIT, AZ) = 40\%$

$$\begin{aligned} E(\text{death})_{VIPIT} &= d \times \frac{1}{100,000} \times \frac{40}{100} \\ &= 246,700 \times \frac{4}{1,000,000} \\ &\approx 1 \end{aligned}$$

If the second dose of the AstraZeneca vaccine is not associated with increased and renewed risk for VIPIT, given the current evidence our best estimate for the number of death associated with AstraZeneca vaccination campaign for front-line workers would be 1. If, however, we assume that the second dose will pose an additional risk of VIPIT, delivering an additional 300,000 doses of the AstraZeneca vaccine will likely double this estimate, for an expected mortality of 2 persons in BC.

We used a compartmental model of transmission and vaccination of COVID-19 in BC to estimate benefits of immediately continuing the front-line workers vaccination program using the AstraZeneca vaccine.

We compared immediately prioritizing essential workers for a vaccine (Scenario A) and delaying it until after those over 70 are fully vaccinated (Scenario B).

In our analysis, scenario A led to 39994 fewer cases of COVID-19, 547 fewer hospitalizations, 106 fewer deaths, and 1824 fewer cases of Long COVID, assuming  $R_0 = 1.3$  and that vaccine effectiveness in preventing transmission is on average 60%. Figure 2 shows results for a wider range of  $R_0$  and efficacy against infection values.




Figure 1. your caption





Figure 2. COVID-19 outcomes under different vaccination scenarios



Mortality Risk from April 1st to July 1st, 2021,  
based on receiving two doses of the AstraZeneca vaccine

**Figure 3.** Mortality risk comparison for different age groups

### 3.2. *Harm-Benefit From a Personal Perspective*

## 4. Discussion

In its analysis of AstraZeneca vaccine, NACI weighed the risk of adverse events against the age-stratified risk of mortality due to COVID-19, pending an overall risk-assessment. However, the benefits of the AstraZeneca vaccine go beyond preventing COVID-related mortality and include protection against more common COVID complications in younger adults including severe disease, hospitalizations, and Long COVID. The recent sharp decline of COVID-19 cases in the UK suggests that the AstraZeneca vaccine might also prevent onward transmission of the virus (Our World in Data 2021).

The number of confirmed daily COVID-19 cases in the UK has plummeted from about 60,000 cases a day in early January 2021 when a national lockdown was imposed and about 3% of the population had received at least one vaccine dose, to about 11,000 cases per day on February 22, 2021 when a roadmap to easing lockdowns was announced to about 6000 cases per day on March 8, 2021 when the first phase of easing public health restrictions was commenced (BBC 2021) and has continuously declined since then to just above 4500 cases as of April 2, 2021 (47% of the UK population have so far received one dose of a COVID-19 vaccine). As about half of all vaccine doses administered in the UK have been AZ vaccines, and based on the estimated AZ vaccine efficacy of about 76% against symptomatic COVID-19 and 64% against any NAAT-positive COVID-19 infection between 22 and 90 days after first dose (Voysey et al. 2021), and real-world single-dose AZ vaccine effectiveness of about 60% against symptomatic COVID-19 and 80% against COVID-19 hospitalization (Public Health England 2021), it is suggested that the AZ vaccine is effective in reducing the overall burden of COVID-19.

Potential prevention of onward transmission with the AstraZeneca vaccine could be especially critical for front-line workers during the current wave of COVID cases. Of note, two recent studies from Toronto, Ontario have showed that neighborhoods with the highest proportion of essential workers had per capita COVID-19 case and death rates that were 2.5-3 folds higher than that of neighborhoods with the lowest share of essential workers (Chagla et al. 2021, Rao et al. (2021)).

#### 4.1. *Doing vs. Allowing Harm*

#### 4.2. *Communications and Vaccine Hesitancy*

### 5. Limitations

We did not consider ethical aspects of vaccine roll-out, and factors such as uptake and vaccine hesitancy, as they were beyond our expertise. Our analysis is based on currently available estimated rates of 1 in million to 1 in 100,000 for VIPIT and might need correction should higher rates of this complication be reported.

We have not considered potential sex differences in the risk for VIPIT. Although cases identified to date have been predominantly female, it remains unclear whether this was due to more females receiving the AstraZeneca vaccine or due to an intrinsic difference in risk.

### 6. Conclusions

dfs sdf sf

### References

- BBC. 2021. "Lockdown: Boris Johnson unveils plan to end England restrictions by 21 June." Accessed 2021-04-04. <https://www.bbc.com/news/uk-56158405>.
- Bubar, Kate M., Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H. Grad, and Daniel B. Larremore. 2021. "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus." *Science (New York, N.Y.)* 371 (6532): 916–921.
- Chagla, Zain, Huiting Ma, Beate Sander, Stefan D. Baral, and Sharmistha Mishra. 2021. "Characterizing the disproportionate burden of SARS-CoV-2 variants of concern among essential workers in the Greater Toronto Area, Canada." *medRxiv* 2021.03.22.21254127. Publisher: Cold Spring Harbor Laboratory Press, Accessed 2021-04-04. <https://www.medrxiv.org/content/10.1101/2021.03.22.21254127v1>.
- EMA. 2021. *COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets*. Technical Report. European Medicines Agency. Accessed 2021-04-02. <https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots>.
- Government of Canada. 2021. *Vaccines for COVID-19: Shipments and deliveries*. Technical Report. Government of Canada. Accessed 2021-04-03. <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks/covid-19-vaccine-treatment/vaccine-rollout.html#a4e>.
- MHRA. 2021. *Coronavirus vaccine - weekly summary of Yellow Card reporting*. Technical Report. Medicines & Healthcare Products Regulatory Agency. Accessed 2021-04-03. <https://www.gov.uk/government/>

- publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.
- Mulberry, N., P. Tupper, E. Kirwin, C. McCabe, and C. Colijn. 2021. "Vaccine Rollout Strategies: The Case for Vaccinating Essential Workers Early." *medRxiv* 2021.02.23.21252309. Publisher: Cold Spring Harbor Laboratory Press, Accessed 2021-04-03. <https://www.medrxiv.org/content/10.1101/2021.02.23.21252309v1>.
- NACI. 2021. *NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults*. Technical Report. National Advisory Committee on Immunization (NACI). Accessed 2021-04-03. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommended-use-astrazeneca-covid-19-vaccine-younger-adults.html>.
- Our World in Data. 2021. *COVID-19 Data Explorer: Daily new confirmed COVID-19 cases per million people*. Technical Report. University of Oxford. Accessed 2021-04-04. <https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=40..latest&pickerSort=asc&pickerMetric=location&Metric=Confirmed+cases&Interval=7-day+rolling+average&Relative+to+Population=true&Align+outbreaks=false&country=~GBR>.
- PEI. 2021. *COVID-19 Vaccine AstraZeneca - Safety assessment result: The vaccine is safe and effective in the fight against COVID-19*. Technical Report. Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicine. Accessed 2021-04-02. <https://www.pei.de/EN/newsroom/hp-news/2021/210319-covid-19-vaccine-astrazeneca-safety-assessment-result-vaccine-safe-and-effective.html>.
- Public Health England. 2021. *1Public Health England vaccine effectiveness report*. Technical Report. Accessed 2021-04-04. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/971017/SP\\_PH\\_\\_VE\\_report\\_20210317\\_CC\\_JLB.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/971017/SP_PH__VE_report_20210317_CC_JLB.pdf).
- Rao, Amrita, Huiting Ma, Gary Moloney, Jeff Kwong, Peter Juni, Beate Sander, Rafal Kustra, Stefan Baral, and Sharmistha Mishra. 2021. *A disproportionate epidemic: COVID-19 cases and deaths among essential workers in Toronto, Canada*.
- Voysey, Merryn, Sue Ann Costa Clemens, Shabir A. Madhi, Lily Y. Weckx, Pedro M. Folegatti, Parvinder K. Aley, Brian Angus, et al. 2021. "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials." *The Lancet* 397 (10277): 881–891. Publisher: Elsevier, Accessed 2021-04-04. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00432-3/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/abstract).